scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
36 hedge funds and large institutions have $29.5M invested in scPharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
3% more funds holding
Funds holding: 35 → 36 (+1)
1.13% less ownership
Funds ownership: 43.39% → 42.26% (-1.1%)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
38% less capital invested
Capital invested by funds: $47.3M → $29.5M (-$17.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$93.6K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$83.2K |
| 3 |
BlackRock
New York
|
+$33.3K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$30.2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$9.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$265K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$259K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$252K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$212K |
| 5 |
JP Morgan Chase
New York
|
-$97.8K |
SCPH Hedge Fund Activity: Q4 2018 in Review
36 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q4 2018, worth a combined $29.5M — down 38% from $47.3M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SCPH positions and 2 closed out — a net gain of 1 holder — while 10 added to existing stakes and 13 trimmed.
The largest buyer was UBS Group, adding an estimated $93.6K. The largest seller was AWM Investment Company, cutting an estimated $265K.
- 36 institutional investors held scPharmaceuticals (SCPH) as of Q4 2018, up from 35 in Q3 2018.
- Funds reported $29.5M of scPharmaceuticals stock for Q4 2018, down 38% quarter-over-quarter.
- 3 funds opened new scPharmaceuticals positions in Q4 2018 and 2 closed out, a net change of +1 holder.
- The largest scPharmaceuticals buyer in Q4 2018 was UBS Group, an estimated $93.6K added.
- The largest scPharmaceuticals seller in Q4 2018 was AWM Investment Company, an estimated $265K sold.
Based on aggregated 13F filings for Q4 2018.